Collaboration to Undertake HIV Resistance Testing in Africa
|
By LabMedica International staff writers Posted on 06 Aug 2012 |
Sequencing-based diagnostics for human immunodeficiency virus (HIV)-infected individuals will be carried out in Africa in order to determine resistance to antiretroviral drugs.
Life Technologies Corp. (Carlsbad, CA, USA) is collaborating with the Southern African Treatment and Resistance Network (SATuRN) to develop a simple-to-answer solution for antiretroviral (ARV) drug resistance testing, which is being made available to African partners at a reasonable cost per test. The test can be run on Life's Applied Biosystems line of Sanger sequencing instruments, which are broadly installed in African hospitals and HIV-testing centers.
Antiretroviral (ARV) drugs for HIV treatment are becoming increasingly available in the developing world but resistance to these drugs develops in many HIV-infected individuals. Resistance can be monitored by genetic sequencing of two viral genes, but current costs have made routine use prohibitive in most African countries.
The methods developed as part of this collaboration have the potential to become the most accurate and cost-effective methods for the diagnosis of resistance pathogens in Africa and the referral of patients for appropriate care. The price of DNA/RNA genotyping is rapidly decreasing as technology evolves rapidly, and the software applications to be used and further developed are all open source and available in Africa.
Additional collaborators on the test development include the Stanford HIV Drug Resistance Database).
"We have trained 1,315 physicians and medical personnel on the interpretation of HIV drug resistance in southern Africa. The region has more than 2 million patients on ARV treatment, and we believe that now is the time for the use of genotyping technology to fight the battle against drug resistance," said Dr. Tulio de Oliveira, director of SATuRN and senior researcher at Wellcome Trust-Africa Centre. "This partnership with LIFE will allow more laboratories to use genotyping techniques, and large surveys on drug resistance to be produced to inform national department of health and policy makers in the region."
SATuRN is a consortium of virologists, clinicians, epidemiologists, bioinformaticians, policy makers, public health specialists, and social scientists working on HIV treatment and care in southern Africa. SATuRN has developed an approach to virological failure clinical management that ensures the delivery of drug resistance genotyping and clinical management to remote clinics without them needing elaborate computer systems or infectious disease specialists on site.
By applying telemedicine and off site laboratories, specialists and physicians from medical centers across the world can review cases, including clinical and resistance data, and give feedback and advice to the clinician managing the patient at the primary clinic.
Life Technologies Corp. is a global biotechnology company. It has more than 50,000 products for agricultural biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety, and animal health.
Related Links:
Life Technologies Corp.
Saturn
Stanford HIV Drug Resistance Database
Life Technologies Corp. (Carlsbad, CA, USA) is collaborating with the Southern African Treatment and Resistance Network (SATuRN) to develop a simple-to-answer solution for antiretroviral (ARV) drug resistance testing, which is being made available to African partners at a reasonable cost per test. The test can be run on Life's Applied Biosystems line of Sanger sequencing instruments, which are broadly installed in African hospitals and HIV-testing centers.
Antiretroviral (ARV) drugs for HIV treatment are becoming increasingly available in the developing world but resistance to these drugs develops in many HIV-infected individuals. Resistance can be monitored by genetic sequencing of two viral genes, but current costs have made routine use prohibitive in most African countries.
The methods developed as part of this collaboration have the potential to become the most accurate and cost-effective methods for the diagnosis of resistance pathogens in Africa and the referral of patients for appropriate care. The price of DNA/RNA genotyping is rapidly decreasing as technology evolves rapidly, and the software applications to be used and further developed are all open source and available in Africa.
Additional collaborators on the test development include the Stanford HIV Drug Resistance Database).
"We have trained 1,315 physicians and medical personnel on the interpretation of HIV drug resistance in southern Africa. The region has more than 2 million patients on ARV treatment, and we believe that now is the time for the use of genotyping technology to fight the battle against drug resistance," said Dr. Tulio de Oliveira, director of SATuRN and senior researcher at Wellcome Trust-Africa Centre. "This partnership with LIFE will allow more laboratories to use genotyping techniques, and large surveys on drug resistance to be produced to inform national department of health and policy makers in the region."
SATuRN is a consortium of virologists, clinicians, epidemiologists, bioinformaticians, policy makers, public health specialists, and social scientists working on HIV treatment and care in southern Africa. SATuRN has developed an approach to virological failure clinical management that ensures the delivery of drug resistance genotyping and clinical management to remote clinics without them needing elaborate computer systems or infectious disease specialists on site.
By applying telemedicine and off site laboratories, specialists and physicians from medical centers across the world can review cases, including clinical and resistance data, and give feedback and advice to the clinician managing the patient at the primary clinic.
Life Technologies Corp. is a global biotechnology company. It has more than 50,000 products for agricultural biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety, and animal health.
Related Links:
Life Technologies Corp.
Saturn
Stanford HIV Drug Resistance Database
Latest Microbiology News
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
- mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
- Syndromic Panel Enables Rapid Identification of Bloodstream Infections
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








